You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

aXitinib

( ax-I-ti-nib )
Funding:
Exceptional Access Program
  • aXitinib - For the treatment of metastatic renal cell carcinoma of clear cell histology (second-line), according to clinical criteria
Other Name(s): Inlyta® (Pfizer)
Appearance: Tablets in various strengths and shapes

You might also be interested in